Pre-clinical Bruker Albira Si PET/SPECT/CT imaging system

点击翻译按钮获取中文摘要

PROJECT SUMMARY/ABSTRACT The Department of Radiology at the Stanford School of Medicine is a preeminent institution renown for developing next generation imaging technology, molecular imaging, in vitro diagnostics, image-guided therapeutics, and informatics for precision health. Our Molecular Imaging Program at Stanford (MIPS), a highly regarded interdisciplinary research division established in 2003, brings together scientists and physicians who share a common interest in developing and using state-of-the-art imaging technology and developing molecular imaging assays for studying intact biological systems. There is now a pressing unmet programmatic need for a multimodal small animal imaging system that offers state-of-the-art imaging available in the Bruker Albira Si PET/SPECT/CT. It will be an enabling technology at Stanford, creating new research opportunities for multi- tracer imaging, significantly broadening our repertoire of radionuclides beyond positron-emitters and accelerating novel radiopharmaceutical development and clinical translation in our theragnostics program. It will allow sunsetting of our once-state-of-the-art, but now end-of-life workhorse Inveon PET/CT, which has experienced increasing downtime due to failures. It will be placed in our comprehensive small animal imaging facility as a Stanford shared resource and supported by a team of PhD-level senior scientists. An integrated trimodal imaging system will immediately contribute to our well-established and growing radionuclide-based biomarker discovery program in diagnostics and radioligand therapy. The Major and Minor users we have assembled reflect junior through senior faculty with NIH-funded research projects and includes highly accomplished experts in their fields. They are particularly interested in multi-tracer applications and, therefore, an integrated system combining SPECT, PET and CT is especially needed. The nuclear imaging modalities would support our researchers who study image-guided drug delivery, cancer biology, neurological diseases, cancer cell and gene therapies, and immunity and immunotherapy, in addition to developing novel diagnostic and theragnostic radiopharmaceuticals and imaging strategies. SPECT is essential for researchers who need access to biomarkers outside of those for PET and for imaging more than one target concurrently. Both modalities, when combined with anatomical CT, are essential to advance novel radiopharmaceuticals from discovery to first-in-human clinical translation, and will be central to our expanding theragnostics activities. The addition of this instrument will converge with programmatic activities at Stanford: new state-of-the-art cyclotron and radiochemistry facility, first designated comprehensive Radiopharmaceutical Therapy Center of Excellence, growing interest in theragnostics and biomarker discovery, and new educational opportunities in biomedical physics, imaging and radionuclide-based therapy. The Albira system will create novel opportunities in small animal research and synergize with Stanford’s long-range vision to lead in biomedical innovation and advanced precision medicine.